Medicenna Therapeutics Appoints Humphrey Gardner, M.D., As Chief Medical Officer October 10, 2023 At 07:08 Am Edt

Oct 10, 2023•almost 2 years ago

Position

Chief Medical Officer

Company

Medicenna

Humphrey Gardner

TorontoHealth CareTherapeuticsBiotechnology

Description

TORONTO and HOUSTON , Oct. 10, 2023 -- Medicenna Therapeutics Corp. , a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner , M.D., as Chief Medical Officer to lead the development strategy and execution of Medicenna’s clinical programs.

Company Information

Company

Medicenna

Location

Toronto, Ontario, Canada

About

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Humphrey hidden